Phase 2 Oesophageal Cancer Trial, Recruiting NCT06067438 Sponsor: OHSU Knight Cancer Institute Condition: Oesophageal Cancer
Back to Oesophageal Cancer

Phase 2 Oesophageal Cancer Trial, Recruiting

NCT06067438
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are scheduled to have a minimally invasive esophageal (food pipe) surgery for cancer, abnormal cell changes in the food pipe, or problems with how the food pipe moves food
  • People who are 18 years of age or older
  • People who are able to understand the study and are willing to sign a consent form agreeing to take part

Who may not be able to join:

  • People who have a history of a heart rhythm problem called atrial fibrillation (either ongoing or occasional) or a related condition called atrial flutter
  • People who have had a serious reaction to a heart medication called amiodarone in the past, or for whom that medication is not considered safe (for example, due to lung, liver, or thyroid problems)
  • People who are already taking amiodarone as a regular daily medication before surgery
  • People who develop an irregular heart rhythm called atrial fibrillation during the surgery itself
  • People who are pregnant (a negative pregnancy test is required on the day of surgery for people who could become pregnant)
  • People who are currently breastfeeding or chest feeding
  • People whose esophageal surgery was started but not completed
  • People whose heart electrical reading (called an ECG or EKG), taken within the last 30 days, shows a certain measurement called QTcF above 500 when their heart rate is between 60 and 100 beats per minute
  • People with a resting heart rate between 50 and 59 beats per minute may require additional heart testing before the trial site can confirm eligibility — this involves checking whether the heart rate rises sufficiently during light exercise or a formal stress test (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
OHSU Knight Cancer Institute
Registry
ClinicalTrials.gov
Start date
21 June 2024
Est. completion
30 August 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Development of atrial fibrillation (AF), or completion of seven-day course of amiodarone

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov